New study by James Frank, Ph.D., reveals use of miniature device with photoswitchable properties implanted in the brains of mice.

An OpEd, written by Alex Foster, M.D., M.P.H., and Ben Hoffman, M.D., supports the safe re-opening of in-person learning to benefit the well-being of children.

Carlos Crespo, Dr.P.H. comments on expectations for COVID-19 in 2021. He warns, “The worst is yet to come. Primarily because we are right now at a very unique spot where people are traveling and this is the scary part.”

Story features Tanya Denne, N.D., a Baker City native and former OHSU volunteer who is working to analyze the neuroprotective properties of the plant Mucana for its potential in treating Parkinson’s disease.

In a story about the rollout of vaccines nationwide, Mark Slifka, Ph.D., says it will take time before masks and other public health measures are no longer necessary. He says, “It will occur when the community is immune, then the transmissions go down, and then communities can drop the mandates.”

Lawrence Furnstahl is listed among 100 chief financial officers to know among U.S. academic medical centers.

Ximena Levander, M.D., is quoted in update of story about the mental health burden of COVID-19, including the effect on addiction medicine.

Derick Du Vivier, M.D., Kelly Gonzales, Ph.D., M.P.H. and Kalani Raphael, M.D. are named to 27-member Vaccine Advisory Committee of the Oregon Health Authority.

In a story about the UK’s approval of AstraZeneca’s vaccine, Marcel Curlin, M.D., says, “Before it becomes available to the public (in the U.S.), it’s going to go through the FDA process, which is an independent and separate review process. … But coming in with that background of it having already been approved in the U.K. is just good news.”

In a Portland Business Tribune article on how businesses were affected in 2020, Tom Beer, M.D., says “We've all had to adjust as we navigate the changing COVID-19 landscape, and the team at the Knight Cancer Institute was able to continue to offer cutting-edge clinical trial and treatment options for our patients who need it most."